RE:RE:RE:u guys are crazy..............
Baldstock:-
I looked at the product description of easymo and it just seems to be a device used to move a hair follicle from one area of the scalp to another with possibly no scaring. If my understanding is accurate, comparing this product (an improvement on the current procedure) to game changers like RCH01 and Dermaprecise is like comparing apples to oranges.
The problem with Replicel Life Sciences is that they have a questionable business model which cannot be implemented by the long-time CEO. Companies do not appear to be willing to spend money upfront on research in exchange for a split of the revenue generated following the approval of the product. The company has only signed up 2 companies (YOFTO and Mainpointe) in the seven plus years I have followed the news.The CEO has also shown very little ability to attract partners. As a matter of fact, potential partners may look at the Company and see a trail of broken promises experienced by partners, common shaeholders and preferred shareholders.